The European Patent Office (EPO) has granted patent EP3765476B1, titled "MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES." This patent, effective March 18, 2026, pertains to specific modified oligonucleotides designed for therapeutic applications in treating tauopathies, a class of neurodegenerative diseases. The grant signifies the EPO's recognition of the invention's novelty and inventive step within the specified classifications.

This patent grant primarily impacts pharmaceutical and biotechnology companies involved in the research and development of treatments for neurodegenerative diseases. While it does not impose direct compliance obligations on other entities, it establishes intellectual property rights that may influence market exclusivity and competitive landscapes for tauopathy treatments. Companies operating in this therapeutic area should be aware of this granted patent and its potential implications for their own research and development pipelines.